Results 291 to 300 of about 8,733,364 (311)

Preclinical Development of Molecular-Targeted Agents for Cancer

Nature Reviews Clinical Oncology, 2011
Alberto Ocana, Ian F Tannock, Lillian Siu   +2 more
exaly  

Orthotopic models of cancer for preclinical drug evaluation

European Journal of Cancer, 2004
openaire   +1 more source

Prediction of Antibiotic Resistance: Time for a New Preclinical Paradigm?

Nature Reviews Microbiology, 2017
Dan Andersson, Christian Munck, Morten O A Sommer   +2 more
exaly  

Food and Drug Administration, Partner in Drug Development

Ca-A Cancer Journal for Clinicians, 2006
Jérôme W Yates, J W Yates
exaly  

Failed Trials for Central Nervous System Disorders Do Not Necessarily Invalidate Preclinical Models and Drug Targets

Nature Reviews Drug Discovery, 2016
Patricio O'Donnell, Malcolm Macleod, Dario Doller   +2 more
exaly  

Insights From Preclinical Choice Models on Treating Drug Addiction

Trends in Pharmacological Sciences, 2017
S Stevens Negus, Matthew L. Banks
exaly  

Preclinical evaluation of anti-CD269 antibody–drug conjugates

European Journal of Cancer, 2016
A. Palfi, M. Kulke, C. Mueller, C. Lutz, A. Pahl, T. Hechler   +5 more
openaire   +1 more source

Advances in the Preclinical Testing of Cancer Therapeutic Hypotheses

Nature Reviews Drug Discovery, 2011
William R Sellers, Giordano Caponigro
exaly  

Preclinical evaluation of flesinoxan as a potential anxiolytic and antidepressant drug

European Journal of Pharmacology, 1990
J. Schipper, M. Tulp, H. Sybesma, F. Krijzer, J. Mos, J. vd Heyden, B. Olivier   +6 more
openaire   +1 more source

Toxicology and Epigenetics

Medical Epigenetics, 2016
exaly